These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30670375)

  • 1. Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses.
    Berger CT; Rebholz-Chaves B; Recher M; Manigold T; Daikeler T
    Ann Rheum Dis; 2019 Jul; 78(7):1012-1014. PubMed ID: 30670375
    [No Abstract]   [Full Text] [Related]  

  • 2. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
    Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH
    Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis.
    Caplanne D; Le Parc JM; Alexandre JA
    Ann Rheum Dis; 1996 Jun; 55(6):403-4. PubMed ID: 8694583
    [No Abstract]   [Full Text] [Related]  

  • 4. Diagnosing and managing polymyalgia rheumatica and temporal arteritis. Repeated measurements of erythrocyte sedimentation rate are not efficient use of time or resources.
    Roome P
    BMJ; 1997 Aug; 315(7107):550. PubMed ID: 9329329
    [No Abstract]   [Full Text] [Related]  

  • 5. Alpha 1-antichymotrypsin, C-reactive protein and erythrocyte sedimentation rate in polymyalgia rheumatica and giant cell arteritis.
    Pountain GD; Calvin J; Hazleman BL
    Br J Rheumatol; 1994 Jun; 33(6):550-4. PubMed ID: 8205403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymyalgia rheumatica and giant cell arteritis.
    Ettlinger RE; Hunder GG; Ward LE
    Annu Rev Med; 1978; 29():15-22. PubMed ID: 348031
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of Treatment on Imaging, Clinical, and Serologic Assessments of Disease Activity in Large-vessel Vasculitis.
    Banerjee S; Quinn KA; Gribbons KB; Rosenblum JS; Civelek AC; Novakovich E; Merkel PA; Ahlman MA; Grayson PC
    J Rheumatol; 2020 Jan; 47(1):99-107. PubMed ID: 30877209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica.
    van der Geest KS; Abdulahad WH; Rutgers A; Horst G; Bijzet J; Arends S; Roffel MP; Boots AM; Brouwer E
    Rheumatology (Oxford); 2015 Aug; 54(8):1397-402. PubMed ID: 25724206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of the erythrocyte sedimentation rate to acute phase proteins in polymyalgia rheumatica and giant cell arteritis.
    Park JR; Jones JG; Hazleman BL
    Ann Rheum Dis; 1981 Oct; 40(5):493-5. PubMed ID: 6171213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tocilizumab for treatment of large vessel vasculitis and polymyalgia rheumatica].
    Henes JC; Xenitidis T
    Z Rheumatol; 2013 Jun; 72(5):486-7. PubMed ID: 23615930
    [No Abstract]   [Full Text] [Related]  

  • 11. [Comment on rule of thumb 14. Polymyalgia].
    Michel BA
    Praxis (Bern 1994); 2011 Jun; 100(12):705-6. PubMed ID: 21656497
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.
    Kyle V; Hazleman BL
    Ann Rheum Dis; 1989 Aug; 48(8):658-61. PubMed ID: 2782975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microheterogeneity of alpha 1-antichymotrypsin in the management of giant-cell arteritis and polymyalgia rheumatica.
    Hachulla E; Laine A; Hayem A
    Clin Sci (Lond); 1990 Jun; 78(6):557-64. PubMed ID: 2165887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.
    Loricera J; Blanco R; Hernández JL; Castañeda S; Mera A; Pérez-Pampín E; Peiró E; Humbría A; Calvo-Alén J; Aurrecoechea E; Narváez J; Sánchez-Andrade A; Vela P; Díez E; Mata C; Lluch P; Moll C; Hernández Í; Calvo-Río V; Ortiz-Sanjuán F; González-Vela C; Pina T; González-Gay MÁ
    Semin Arthritis Rheum; 2015 Jun; 44(6):717-23. PubMed ID: 25697557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating levels of IL-1beta, IL-6 and soluble IL-2 receptor in polymyalgia rheumatica and giant cell arteritis and rheumatoid arthritis.
    Pountain G; Hazleman B; Cawston TE
    Br J Rheumatol; 1998 Jul; 37(7):797-8. PubMed ID: 9714363
    [No Abstract]   [Full Text] [Related]  

  • 16. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up.
    Kyle V; Cawston TE; Hazleman BL
    Ann Rheum Dis; 1989 Aug; 48(8):667-71. PubMed ID: 2782977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum C-reactive protein in polymyalgia rheumatica. A prospective serial study.
    Mallya RK; Hind CR; Berry H; Pepys MB
    Arthritis Rheum; 1985 Apr; 28(4):383-7. PubMed ID: 2859021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Polymyalgia rheumatica. Primary symptoms: muscle pain, malaise].
    Nigg C; Naumann UK; Käser L; Vetter W
    Praxis (Bern 1994); 2007 Oct; 96(44):1705-11; quiz 1712-3. PubMed ID: 18018947
    [No Abstract]   [Full Text] [Related]  

  • 19. CRP in the management of polymyalgia rheumatica and giant cell arteritis.
    Schreiber S
    Clin Rheumatol; 1987 Mar; 6(1):97-8. PubMed ID: 3581706
    [No Abstract]   [Full Text] [Related]  

  • 20. Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases.
    Vinicki JP; García-Vicuña R; Arredondo M; López-Bote JP; García-Vadillo JA; Castañeda S; Álvaro-Gracia JM
    Reumatol Clin; 2017; 13(4):210-213. PubMed ID: 27499427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.